drugset / Trial / NCT00295594

Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.

NCT00295594

Phase 3 Completed 627 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelPrevention

Summary

To compare the efficacy and safety of two regimens containing tacrolimus and minimal steroids together with either monoclonal anti-IL2R antibodies (daclizumab) or mycophenolate mofetil.

Timeline

Start
2005-03
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Background Tacrolimus Small molecule

Indications

No indication recorded.